Phase 3 studies

• 11/8/2024

  “Unlock Intellia Therapeutics’ 354% Upside Potential: A Gene-Editing Gem?”

• 10/22/2024

  Annovis Bio’s Phase 3 Trials: Can They Secure Funding?